Aditxt Signs Second Amendment To The Arrangement Agreement With Appili Therapeutics, Targeting September 30 Closing Of The Acquisition; Appili, With A Commercial-Stage Pipeline, Has Raised CAD$100M Towards Developing Therapeutics For The Global Infectious Disease And Biodefense Markets
Portfolio Pulse from Benzinga Newsdesk
Aditxt, Inc. (NASDAQ:ADTX) has signed a second amendment to its arrangement agreement with Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF), targeting a September 30, 2024, closing for the acquisition. Appili has raised CAD $100M for developing therapeutics for infectious diseases and biodefense markets, with two programs potentially eligible for FDA Priority Review Vouchers.
July 25, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aditxt has amended its agreement with Appili Therapeutics, targeting a September 30, 2024, closing for the acquisition. This move could enhance Aditxt's portfolio in the infectious disease and biodefense markets.
The acquisition of Appili Therapeutics by Aditxt is likely to enhance Aditxt's portfolio in the infectious disease and biodefense markets, potentially leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Appili Therapeutics has raised CAD $100M for developing therapeutics and is set to be acquired by Aditxt by September 30, 2024. This could provide a significant boost to Appili's development programs.
The significant funding raised by Appili and its upcoming acquisition by Aditxt could accelerate its development programs, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 100